Yolande RamosPostdoctoral Researcher | Tel.: +31 (0) 71 526 97 44send mail
Yolande Ramos (1970) obtained her Bachelors degree at the University of Utrecht in 1991 and her Master’s degree with specialization tumor biology and neuropharmacology at the Free University of Amsterdam in 1995. After working for a year at the Dept. of Pathology of the Harvard Medical School, Boston, USA, in the laboratory of Prof. dr. Tsai, she started her first PhD in 1996 at the Dept. of Molecular Cell Biology, section Molecular Carcinogenesis with Prof. dr. van der Eb at the University of Leiden, in the laboratory of dr. Jochemsen. Research performed in this period resulted in 2001 in the thesis entitled ‘Analysis of MDMX: functions and expression pattern’.
After several years of research as a post doctoral collaborator of dr. Zantema and dr. van Dam at the Dept. of Molecular Cell Biology while specializing in transcription regulation, she decided to perform a second PhD at the Dept. of Medical Statistics, section Molecular Epidemiology with Prof. dr. Slagboom at the Leiden University Medical Center, in the laboratory of dr. Meulenbelt. This resulted in the thesis, entitled: 'Osteoarthritis, a degenerative disease of the articular joints : towards the implementation of functional genomics in OA'
Currently, dr. Ramos continues her research as a post doctoral scientist in the Osteoarthritis group of the Dept. of Molecular Epidemiology (LUMC) and her work is focused on increasing knowledge of the etiology of osteoarthritis (OA). Dr. Ramos is interested in promoting the unification of genetic analyses and functional studies, in particular in the field of osteoarthritis and skeletal health, which will enhance bench-to-bed transition and the development of precision medicine.
Genetic variants associated with OA are further characterized by applying functional studies with the use of tissues and cells collected from patients undergoing joint replacement surgery such as done for the OA susceptibility gene deiodinase iodothyronine type 2 (DIO2) and osteoprotegerin (OPG). In addition, dr. Ramos endeavors to identify biomarkers that facilitate diagnosis of OA patients at an early stage and that may contribute to distinguish subtypes of OA patients and patients prone to fast progression.